The diet company formerly known as WeightWatchers has filed for bankruptcy after its 62-year-old business model was put under ...

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cut its guidance ...

Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and ...

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on Wednesday, ending a four-year stretch of steady guidance ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo reported first-quarter earnings before interest and taxation (EBIT) of 38.79 billion Danish crowns ($5.90 billion), ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a pill.